Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
AJOB Neurosci ; 15(2): 82-89, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38315212

RESUMEN

The psychedelic psilocybin has shown promise both as treatment for psychiatric conditions and as a means of improving well-being in healthy individuals. In some jurisdictions (e.g., Oregon, USA), psilocybin use for both purposes is or will soon be allowed and yet, public attitudes toward this shift are understudied. We asked a nationally representative sample of 795 US Americans to evaluate the moral status of psilocybin use in an appropriately licensed setting for either treatment of a psychiatric condition or well-being enhancement. Showing strong bipartisan support, participants rated the individual's decision as morally positive in both contexts. These results can inform effective policy-making decisions around supervised psilocybin use, given robust public attitudes as elicited in the context of an innovative regulatory model. We did not explore attitudes to psilocybin use in unsupervised or non-licensed community or social settings.


Asunto(s)
Alucinógenos , Trastornos Mentales , Humanos , Psilocibina/uso terapéutico , Alucinógenos/uso terapéutico , Toma de Decisiones , Política Pública
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA